Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. (Q54310972)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 May 2012

Language	Label	Description	Also known as
English	Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.	scientific article published on 8 May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

author name string

Shengxiang Ren

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Xiaoxia Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Peng Kuang

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Limou Zheng

4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Chunxia Su

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Jiayu Li

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Bing Li

7

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Yongshen Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Lu Liu

9

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Qiong Hu

10

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Jie Zhang

11

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Liang Tang

12

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Xuefei Li

13

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Caicun Zhou

14

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Gerald Schmid-Bindert

15

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

language of work or name

0 references

publication date

8 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

118

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

22

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

5588-5594

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

Global patterns of cancer incidence and mortality rates and trends

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Advances in chemotherapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Non–Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Crizotinib: an anaplastic lymphoma kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

21 January 2018

Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27603

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27603

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/22569898

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54310972&oldid=1773356809"